Home Featured Page 205

Featured

Latest

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

Weekly Psychedelic Policy Briefing: October 12, 2026

Filament Health and ATMA Journey Centers Announce Licensing Agreement

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

COMPASS Pathways announces financial results for the fourth quarter and full...

PT296 – Dr. David Luke – Vital Psychedelic Conversations

Reclaiming Ownership of Your Body With Psychedelics

Tackling Trauma with Pharmahuasca and DMT

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder...

PT295 – Sidarta Ribeiro – Dreams, LSD, and Biopiracy

EDITOR PICKS

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In...

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.